Outcomes of locally advanced gastric and gastroesophageal adenocarcinoma cancers treated with neoadjuvant FLOT in a tertiary care hospital in Pakistan

被引:0
作者
Dawood, Tasneem [1 ]
Rashid, Yasmin Abdul [1 ]
Khan, Saqib Raza [1 ]
Jabbar, Adnan Abdul [2 ]
Zahir, Muhammad Nauman [2 ]
Moosajee, Munira Shabbir [1 ]
机构
[1] Aga Khan Univ Hosp, Dept Med Oncol, Karachi 74800, Pakistan
[2] Dr Ziauddin Hosp, Dept Med Oncol, Karachi 74700, Pakistan
来源
ECANCERMEDICALSCIENCE | 2024年 / 18卷
关键词
gastric cancer; gastroesophageal cancer; pathological response; neoadjuvant; chemotherapy; PERIOPERATIVE CHEMOTHERAPY; ADVANCED ESOPHAGEAL; OXALIPLATIN; JUNCTION; 5-FLUOROURACIL; MULTICENTER; LEUCOVORIN; DOCETAXEL;
D O I
10.3332/ecancer.2024.1705
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and aim: Docetaxel, oxaliplatin, leucovorin and 5-fluorouracil (FLOT) may improve overall survival (OS) in patients with locally advanced gastric and gastroesophageal cancer. Our study aims to determine the pathological response in these patients with the FLOT chemotherapy in the Neoadjuvant setting. This is the first study conducted in our country. Methods: We conducted a retrospective cross-sectional study from March 2018 to December 2020. After ethical review committee approval, all patients who fulfilled the inclusion criteria and received treatment at our tertiary care center were included in the study. SPSS version 22 was used for data analysis. Frequencies and percentages were calculated for categorical. Values were presented as mean +/- standard deviation (SD) for continuous variables. The chi-square test was used to determine the difference between categorical variables. A p-value of <= 0.05 was considered the level of significance. Kaplan-Meier curves were used to calculate survival analysis. Results: Out of 41, 35 patients with locally advanced resectable gastric or gastroesophageal adenocarcinoma were included in our study analysis. The entire cohort had a male predominance, with a mean age of 59. All patients received neoadjuvant FLOT. Pathological treatment response achieved was 77%, of which 66% had partial and 11% had complete response. There is a significant association of pathological response with age, gender, stage, grade, co-morbid and number of chemotherapy cycles received (p-value =<0.05). The OS was 80% with the mean OS was 2.6 years (31 months). Conclusion: Our study shows comparable response rates to other studies conducted internationally. Our findings confirm that FLOT is an effective and well-tolerated perioperative regimen with reasonable response rates in the Pakistani population. A more extensive longitudinal study would ensure these preliminary results in the local patient population.
引用
收藏
页数:11
相关论文
共 28 条
[1]   Does the FLOT regimen a new standard of perioperative chemotherapy for localized gastric cancer? [J].
Adenis, Antoine ;
Samalin, Emmanuelle ;
Mazard, Thibault ;
Portales, Fabienne ;
Mourregot, Anne ;
Ychou, Marc .
BULLETIN DU CANCER, 2020, 107 (01) :54-60
[2]   CheckMate 648: A randomized phase 3 study of nivolumab plus ipilimumab or nivolumab combined with fluorouracil plus cisplatin versus fluorouracil plus cisplatin in patients with unresectable advanced, recurrent, or metastatic previously untreated esophageal squamous cell carcinoma. [J].
Ajani, Jaffer A. ;
Kato, Ken ;
Doki, Yuichiro ;
Chau, Ian ;
Xynos, Ioannis ;
Balogh, Agnes ;
Kitagawa, Yuko .
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
[3]   Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): A multicenter, randomized phase 3 trial. [J].
Al-Batran, Salah-Eddin ;
Homann, Nils ;
Schmalenberg, Harald ;
Knopp, Hans-Georg ;
Georg .
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[4]   Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial [J].
Al-Batran, Salah-Eddin ;
Hofheinz, Ralf D. ;
Pauligk, Claudia ;
Kopp, Hans-Georg ;
Haag, Georg Martin ;
Luley, Kim Barbara ;
Meiler, Johannes ;
Homann, Nils ;
Lorenzen, Sylvie ;
Schmalenberg, Harald ;
Probst, Stephan ;
Koenigsmann, Michael ;
Egger, Matthias ;
Prasnikar, Nicole ;
Caca, Karel ;
Trojan, Joerg ;
Martens, Uwe M. ;
Block, Andreas ;
Fischbach, Wolfgang ;
Mahlberg, Rolf ;
Clemens, Michael ;
Illerhaus, Gerald ;
Zirlik, Katja ;
Behringer, Dirk M. ;
Schmiegel, Wolff ;
Pohl, Michael ;
Heike, Michael ;
Ronellenfitsch, Ulrich ;
Schuler, Martin ;
Bechstein, Wolf O. ;
Koenigsrainer, Alfred ;
Gaiser, Timo ;
Schirmacher, Peter ;
Hozaeel, Wael ;
Reichart, Alexander ;
Goetze, Thorsten O. ;
Sievert, Mark ;
Jaeger, Elke ;
Moenig, Stefan ;
Tannapfel, Andrea .
LANCET ONCOLOGY, 2016, 17 (12) :1697-1708
[5]   The decline in stomach cancer mortality: exploration of future trends in seven European countries [J].
Amiri, Masoud ;
Janssen, Fanny ;
Kunst, Anton E. .
EUROPEAN JOURNAL OF EPIDEMIOLOGY, 2011, 26 (01) :23-28
[6]   Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study [J].
Andre, Thierry ;
Tougeron, David ;
Piessen, Guillaume ;
de la Fouchardiere, Christelle ;
Louvet, Christophe ;
Adenis, Antoine ;
Jary, Marine ;
Tournigand, Christophe ;
Aparicio, Thomas ;
Desrame, Jerome ;
Lievre, Astrid ;
Garcia-Larnicol, Marie-Line ;
Pudlarz, Thomas ;
Cohen, Romain ;
Memmi, Salome ;
Vernerey, Dewi ;
Henriques, Julie ;
Lefevre, Jeremie H. ;
Svrcek, Magali .
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (02) :255-+
[7]   Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial [J].
Bang, Yung-Jue ;
Van Cutsem, Eric ;
Feyereislova, Andrea ;
Chung, Hyun C. ;
Shen, Lin ;
Sawaki, Akira ;
Lordick, Florian ;
Ohtsu, Atsushi ;
Omuro, Yasushi ;
Satoh, Taroh ;
Aprile, Giuseppe ;
Kulikov, Evgeny ;
Hill, Julie ;
Lehle, Michaela ;
Ruschoff, Josef ;
Kang, Yoon-Koo .
LANCET, 2010, 376 (9742) :687-697
[8]   Comprehensive molecular characterization of gastric adenocarcinoma [J].
Bass, Adam J. ;
Thorsson, Vesteinn ;
Shmulevich, Ilya ;
Reynolds, Sheila M. ;
Miller, Michael ;
Bernard, Brady ;
Hinoue, Toshinori ;
Laird, Peter W. ;
Curtis, Christina ;
Shen, Hui ;
Weisenberger, Daniel J. ;
Schultz, Nikolaus ;
Shen, Ronglai ;
Weinhold, Nils ;
Keiser, David P. ;
Bowlby, Reanne ;
Sipahimalani, Payal ;
Cherniack, Andrew D. ;
Getz, Gad ;
Liu, Yingchun ;
Noble, Michael S. ;
Pedamallu, Chandra ;
Sougnez, Carrie ;
Taylor-Weiner, Amaro ;
Akbani, Rehan ;
Lee, Ju-Seog ;
Liu, Wenbin ;
Mills, Gordon B. ;
Yang, Da ;
Zhang, Wei ;
Pantazi, Angeliki ;
Parfenov, Michael ;
Gulley, Margaret ;
Piazuelo, M. Blanca ;
Schneider, Barbara G. ;
Kim, Jihun ;
Boussioutas, Alex ;
Sheth, Margi ;
Demchok, John A. ;
Rabkin, Charles S. ;
Willis, Joseph E. ;
Ng, Sam ;
Garman, Katherine ;
Beer, David G. ;
Pennathur, Arjun ;
Raphael, Benjamin J. ;
Wu, Hsin-Ta ;
Odze, Robert ;
Kim, Hark K. ;
Bowen, Jay .
NATURE, 2014, 513 (7517) :202-209
[9]   Perioperative Therapy of Oesophagogastric Adenocarcinoma: Mainstay and Future Directions [J].
Bose, Katrin ;
Franck, Caspar ;
Mueller, Meike N. ;
Canbay, Ali ;
Link, Alexander ;
Venerito, Marino .
GASTROENTEROLOGY RESEARCH AND PRACTICE, 2017, 2017
[10]  
Bosman FT., 2010, WHO CLASSIFICATION T